HC Wainwright restated their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH - Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $18.00 target price on the stock.
scPharmaceuticals Price Performance
SCPH stock traded up $0.07 during trading on Wednesday, reaching $4.57. 828,272 shares of the company were exchanged, compared to its average volume of 221,735. The company has a market cap of $164.75 million, a P/E ratio of -3.22 and a beta of 0.09. scPharmaceuticals has a 52-week low of $4.01 and a 52-week high of $11.75. The stock's 50 day moving average price is $4.91 and its 200 day moving average price is $5.39. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.40 and a current ratio of 7.08.
scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The firm had revenue of $6.10 million for the quarter, compared to the consensus estimate of $6.50 million. scPharmaceuticals had a negative net margin of 403.22% and a negative return on equity of 97.18%. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. As a group, analysts predict that scPharmaceuticals will post -1.47 earnings per share for the current fiscal year.
Institutional Trading of scPharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the business. Perkins Capital Management Inc. purchased a new stake in shares of scPharmaceuticals in the first quarter valued at about $53,000. IPG Investment Advisors LLC acquired a new position in shares of scPharmaceuticals in the fourth quarter valued at approximately $75,000. Assenagon Asset Management S.A. acquired a new position in shares of scPharmaceuticals in the first quarter valued at approximately $100,000. Thomasville National Bank raised its position in shares of scPharmaceuticals by 11.5% in the first quarter. Thomasville National Bank now owns 36,800 shares of the company's stock valued at $185,000 after buying an additional 3,800 shares during the last quarter. Finally, Balanced Rock Investment Advisors LLC raised its position in shares of scPharmaceuticals by 9.2% in the first quarter. Balanced Rock Investment Advisors LLC now owns 57,248 shares of the company's stock valued at $287,000 after buying an additional 4,827 shares during the last quarter. Hedge funds and other institutional investors own 89.52% of the company's stock.
About scPharmaceuticals
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Further Reading
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
